Ongoing collection of blood and tumor samples from people with lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, longitudinal cohort at Nantes University Hospital collects serial blood, PBMC, Paxgene, and tumor biopsy samples from adults with various lung cancer types and stages, along with healthy volunteer controls. Participants who are newly diagnosed or have metastatic disease and who receive systemic therapy (chemotherapy, targeted therapy, immunotherapy, or unblinded trial drugs) provide samples at scheduled visits to link molecular data with treatments and outcomes. All participants sign informed consent for biobanking and long-term storage for molecular and translational research, including an ancillary arm for KRAS G12C–mutant metastatic NSCLC treated with KRAS inhibitors. The design captures real-world diversity in age, comorbidities, and co-medications that are often underrepresented in controlled trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients :

* Adult
* Patient newly diagnosed with NSCLC or CPC
* Cared for at Nantes University Hospital
* Affiliated or beneficiaries of a social security scheme or similar
* Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding).
* Having agreed to participate in this study by signing the biocollection consent.

Healthy subjects :

* Adult
* Affiliated or beneficiaries of a social security or similar scheme
* Who have agreed to participate in this study by signing the Biocollection consent form.
* No known infectious pathology
* No known history of cancer
* No known history of chronic autoimmune disease
* No background immuno-suppressive treatment

Ancillary Study :

-Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in combination.

Exclusion Criteria:

Patients :

* Previous anticancer treatment for Lung cancer
* Patients who have not consented to participate in the BREATHE collection
* History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
* Inclusion in a therapeutic trial with blinded treatment
* Patients under guardianship
* Patients with AME.
* Pregnant or breast-feeding women

Healthy subjects :

* Person under guardianship
* Person benefiting from AME (State medical aid)
* Pregnant or breast-feeding women

Ancillary Study :

\- Pregnant or breast-feeding women

Where it's running

• CHU Nantes
  Nantes, France Recruiting
• CHU d'Angers
  Angers, France Not yet recruiting
• CHU Rennes
  Rennes, France Not yet recruiting
• CHU Tours
  Tours, France Not yet recruiting

Study contacts

• Study coordinator: Elvire PONS-TOSTIVINT, MD PhD
• Email: elvire.pons@chu-nantes.fr
• Phone: 02.40.16.59.30

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• Testing a new drug for adults with advanced solid tumors

  This study is testing a new drug for adults with advanced solid tumors that haven't responded to other treatments to see if it can help them.

  Recruiting at 43 sites Phase 1 Seagen Inc. · Phoenix, Arizona and 47 other locations · NCT06131840

• Evaluating a new imaging technique for lung cancer diagnosis

  This study is testing a new imaging technique during lung procedures to see if it helps doctors diagnose lung cancer more accurately in patients with suspicious lung lesions.

  Recruiting at 5 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · New York, New York and 4 other locations · NCT06079970

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.